AleAnna (NASDAQ:ANNA) vs. Corbus Pharmaceuticals (NASDAQ:CRBP) Head to Head Review

Corbus Pharmaceuticals (NASDAQ:CRBP) and AleAnna (NASDAQ:ANNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Risk & Volatility

Corbus Pharmaceuticals has a beta of 2.84, meaning that its stock price is 184% more volatile than the S&P 500. Comparatively, AleAnna has a beta of -1.21, meaning that its stock price is 221% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Corbus Pharmaceuticals and AleAnna, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2	0	6	2	2.80
AleAnna	1	0	0	0	1.00

Corbus Pharmaceuticals presently has a consensus target price of $43.71, suggesting a potential upside of 338.02%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than AleAnna.

Earnings & Valuation

This table compares Corbus Pharmaceuticals and AleAnna”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.98)	-1.67
AleAnna	$25.04 million	19.32	-$12.34 million	$0.04	181.50

AleAnna has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.1% of AleAnna shares are owned by institutional investors. 3.6% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 42.9% of AleAnna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Corbus Pharmaceuticals and AleAnna’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-65.76%	-57.88%
AleAnna	-46.01%	-14.90%	-8.74%

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About AleAnna

AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.